In regulatory filings, Neurocrine disclosed that its director Gary Lyons and Chief Medical Officer Eiry Roberts each sold 10K shares of common stock on December 22nd in separate transactions of $1.3M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target raised to $145 from $125 at Barclays
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- Neurocrine price target raised by $17 at Wells Fargo, here’s why
- Neurocrine initiated with neutral view at Citi, here’s why
- Neurocrine initiated with neutral view at Citi
Questions or Comments about the article? Write to editor@tipranks.com